Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Dexmedetomidine and Long-term Survival in Older Cancer Surgery Patients
NCT06030804Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in cancer (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Progression-free survival at 3 years. Started Sep 2023; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06030804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030804.